Last reviewed · How we verify
Intermediate dose tinzaparin
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboprophylaxis in surgical patients, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.
At a glance
| Generic name | Intermediate dose tinzaparin |
|---|---|
| Also known as | tinzaparin, Innohep |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect target); Coagulation factors Xa and IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Hematology |
| Phase | FDA-approved |
Mechanism of action
Tinzaparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,000 and 10,000 Da. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa (anti-Xa activity) with some anti-IIa activity. The intermediate dose formulation provides a standardized anticoagulant effect suitable for thromboprophylaxis and treatment of thromboembolic disorders.
Approved indications
- Thromboprophylaxis in surgical patients
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT (PHASE4)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: